- Home
- KALA vs CISS Comparison
KALA vs CISS Comparison
Compare KALA & CISS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- CISS
- Stock Information
- Founded
- KALA 2009
- CISS 2022
- Country
- KALA United States
- CISS Greece
- Employees
- KALA N/A
- CISS N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- CISS Marine Transportation
- Sector
- KALA Health Care
- CISS Consumer Discretionary
- Exchange
- KALA Nasdaq
- CISS Nasdaq
- Market Cap
- KALA 5.1M
- CISS 5.3M
- IPO Year
- KALA 2017
- CISS N/A
- Fundamental
- Price
- KALA $0.66
- CISS $1.69
- Analyst Decision
- KALA Buy
- CISS
- Analyst Count
- KALA 3
- CISS 0
- Target Price
- KALA $31.50
- CISS N/A
- AVG Volume (30 Days)
- KALA 244.4K
- CISS 114.8K
- Earning Date
- KALA 11-07-2025
- CISS 11-18-2025
- Dividend Yield
- KALA N/A
- CISS N/A
- EPS Growth
- KALA N/A
- CISS N/A
- EPS
- KALA N/A
- CISS N/A
- Revenue
- KALA N/A
- CISS $33,613,149.00
- Revenue This Year
- KALA N/A
- CISS N/A
- Revenue Next Year
- KALA N/A
- CISS N/A
- P/E Ratio
- KALA N/A
- CISS $0.29
- Revenue Growth
- KALA N/A
- CISS N/A
- 52 Week Low
- KALA $0.64
- CISS $1.57
- 52 Week High
- KALA $20.60
- CISS $17.25
- Technical
- Relative Strength Index (RSI)
- KALA 27.23
- CISS 31.49
- Support Level
- KALA $0.64
- CISS $1.57
- Resistance Level
- KALA $0.73
- CISS $2.02
- Average True Range (ATR)
- KALA 0.06
- CISS 0.14
- MACD
- KALA 0.32
- CISS -0.03
- Stochastic Oscillator
- KALA 31.24
- CISS 9.45
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of its fleet is approximately 64,000 dwt.